聚乙二醇干扰素治疗慢性丙型肝炎有效性的Meta分析

• 药品评价-循证医学研究 • 上一篇下一篇

聚乙二醇干扰素治疗慢性丙型肝炎有效性的Meta分析

陈平钰,马爱霞

中国药科大学国际医药商学院,中国药科大学国际医药商学院

收稿日期:2014-08-21 修回日期:2014-10-08 出版日期:2014-12-25 发布日期:2014-12-25

Meta-analysis of the Effectiveness on Peginterferon for Chronic Hepatitis C

School of International Pharmaceutical Business,China Pharmaceutical University,Jiangsu Nanjing 211198,China

Received:2014-08-21 Revised:2014-10-08 Online:2014-12-25 Published:2014-12-25

摘要/Abstract

摘要： 目的：系统评价聚乙二醇干扰素基于中国人群治疗慢性丙型肝炎的有效性。方法：检索数据库2004~2014年公开发表的聚乙二醇干扰素治疗慢性丙型肝炎的国内临床试验，以患者持续病毒学应答（SVR）获得率作为临床结果指标进行Meta分析。结果：观察组与对照组SVR获得率有显著差异，其中聚乙二醇干扰素α-2a组SVR获得率有显著差异，聚乙二醇干扰素α-2b组SVR获得率无显著差异。结论：聚乙二醇干扰素可以显著提高中国慢性丙型肝炎患者SVR获得率。其中聚乙二醇干扰素α-2a更具有效性，但聚乙二醇干扰素α-2b安全性更高。

Abstract: Objective：To systematically evaluate the clinical efficacy of peginterferon for Chinese chronic hepatitis C patients. Methods： The domestic chronic hepatitis C clinical trials adopting peginterferon published from 2004 to 2014 were retrieved，and SVR achieving rate was considered as clinical effective index to develop a Meta-analysis.Results： The SVR achieving rate between experimental group and control group was statistically different，among which the SVR achieving rate of the group adopting peginterferon α-2a was statistically different while the group adopting peginterferon α-2b was not.Conclusion： Peginterferon greatly improves the SVR achieving rate for Chinese chronic hepatitis C patients.Furthermore，peginterferon α-2a shows better clinical effect and peginterferon α-2b shows better safety.

陈平钰,马爱霞. 聚乙二醇干扰素治疗慢性丙型肝炎有效性的Meta分析[J]. .

参考文献

[1]Mohd Hanafiah K,Groeger J,Flaxman AD et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence [J]. Hepatology, 2013, 57:1333-1342.
[2]Rao H,Wei L,Lopez-Talavera J,et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection [J]. Gastroenterol Hepatol,2014,29:545–53.
[3]Thomas DL,Thio CL,Martin MP et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus [J]. Nature, 2009, 461:798-801.
[4JADAD AR,MOORE RA,CARROLL D,et al． Assessing the quality of reports of randomized clinical trials: is blinding necessary [J]．Control Clin Trials,1996,17(1):1-12．
[5]钟文昭等. Review Manager(RevMan)——临床医生通向Meta 分析的桥梁[J].循证医学,2003,3(4)：234-246.
[6]马丽娜,陈新月,陈杰,等. 聚乙二醇干扰素治疗慢性丙型肝炎临床疗效、影响因素及安全性分析(附89例临床分析)[J]. 中华实验和临床病毒学杂志,2006,02:42-45.
[7]陈美鸿,周君霞,林庆东. 聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎[J]. 广东医学,2007,12:2016-2017.
[8]刘英辉,李秀平,陈立娟. 聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎[J]. 中国临床医学,2007,06:815-816.
[9]卫梅. 利巴韦林联合聚乙二醇干扰素(哌罗欣)治疗慢性丙肝61例临床观察[J]. 中国实用医药,2011,35:154-155.
[10]朱松涛. 聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎疗效观察[J]. 临床合理用药杂志,2011,07:16-17.
[11]范海清,赵志清,杜普. 聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎疗效观察[J]. 海南医学院学报,2012,03:346-348.
[12]梁超. 聚乙二醇干扰素α-2a与普通干扰素α-2a联合利巴韦林治疗慢性丙型肝炎50例疗效观察[J]. 中国实用医药,2012,09:186-187.
[13]卢雪兰. 聚乙二醇干扰素α-2a治疗慢性丙型肝炎68例临床观察[J]. 临床合理用药杂志,2012,16:74-75.
[14]刘贵章,赵登蕴,李声方,等. 普通干扰素与聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎疗效观察[J]. 实用肝脏病杂志,2013,03:263-264
[15]秦海玲. 不同干扰素联合利巴韦林治疗丙型肝炎的临床疗效及安全性[J]. 中外医疗,2013,14:116 118.
[16]杨定康,李秋水. 长效与短效α-干扰素治疗慢性丙型肝炎疗效观察[J]. 实用肝脏病杂志,2014,01:55-57.
[17]赵文莉,胡勤明,黄飞. 聚乙二醇干扰素α-2a治疗慢性丙型肝炎疗效观察[J]. 中国药师,2014,02:255-257.
[18]樊万虎,张树林. 聚乙二醇化干扰素α-2b联合利巴韦林治疗慢性丙型肝炎40例[J]. 实用医学杂志,2006,21:2516-2518.
[19]罗端德,易建华,蔡淑清,等. 聚乙二醇干扰素α-2b联合利巴韦林治疗慢性丙型肝炎的随机对照临床研究[J]. 中华传染病杂志,2006,03:175-178.
[20]周炳喜,唐芙爱,杨玉秀. 聚乙二醇干扰素α-2b联合利巴韦林治疗慢性丙型肝炎的研究[J]. 实用诊断与治疗杂志,2006,09:628-629 632.
[21]于淑丽,张照华,吕卉,等. 聚乙二醇α-2b干扰素联合利巴韦林治疗慢性丙型肝炎72周随访观察[J]. 中华肝脏病杂志,2007,15(3):231.
[22]Jacobson IM,McHutchison JG,Dusheiko G,et al. Telaprevir for previously untreated chronic hepatitis C virus infection [J]. N Engl J Med, 2011, 364:2405-2416.